SYNAPTOGENIX, INC.
New York, United States · Founded 2019
- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2019
- Business Model
- B2B
- Website
- synaptogenix.com
About
Synaptogenix is a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases. Its lead compound Bryostatin-1 has been studied in NIH-sponsored Phase 2 trials for advanced Alzheimer's disease, demonstrating significant cognitive benefits. The company has also received FDA IND authorization for Bryostatin-1 trials in multiple sclerosis. Note: as of late 2024 the company has pivoted toward an AI/crypto treasury strategy under the TAO Synergies brand.
Summary
SYNAPTOGENIX, INC. is a Biotech company based in New York, United States, founded in 2019.
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/synaptogenix-inc"><img src="https://indexed.vc/api/badge/company/synaptogenix-inc" alt="SYNAPTOGENIX, INC. on Indexed.vc" width="260" height="76" /></a>